Variables | Univariate | Multivariate analysis | |||
---|---|---|---|---|---|
Dead (n = 132) N (%) | Alive (n = 208) N (%) | p-value | HR (95% CI) | p-value | |
Age (years), median (range) | 50 (16–80) | 56 (14–86) | 0.07 |  | – |
Gender, male | 84 (64) | 119 (57) | 0.24 |  | – |
Diagnosis of invasive aspergillosis | Â | Â | 0.001 | Â | 0.023 |
 Definite | 54 (41) | 50/207 (24) |  | 1.5 (1.1, 2.2) |  |
 Probable | 78 (59) | 157/207 (76) |  | Referent |  |
Type of IA infection a | Â | Â | 0.16 | Â | 0.007 |
 Invasive pulmonary infection | 111 (84) | 174 (84) |  | 3.3 (1.5, 7.2) | (0.003) |
 Disseminated infection | 13 (10) | 12 (6) |  | 4.0 (1.6, 10.3) | (0.003) |
 Localized or sinus infection | 8 (6) | 22 (11) |  | Referent |  |
Type of cancer |  |  | 0.05 |  | – |
 Leukemia | 106/131 (81) | 148/205 (72) |  |  |  |
 Lymphoma | 23/131 (18) | 43/205 (21) |  |  |  |
 Myeloma | 2/131 (2) | 14/205 (7) |  |  |  |
Transplantation within 1 year prior to infection | 41/131 (31) | 91 (44) | 0.022 | 0.60 (0.41, 0.88) | 0.008 |
Type of transplantation within prior year | Â | Â | 0.06 | Â | Â |
 Allogeneic transplant | 39/41 (95) | 74/91 (81) |  |  |  |
 Autologous transplant | 2/41 (8) | 17/91 (19) |  |  |  |
Graft vs Host Disease (GVHD) | 29/39 (74) | 53/74 (72) | 0.76 | Â | Â |
Neutropenia (< 500 ANC) at onset of IA | 79/130 (61) | 76/199 (38) | < .0001 |  | – |
Persistent neutropenia | 59/130 (45) | 63/179 (35) | 0.07 |  | – |
Received immunotherapy | 92 (70) | 108/205 (53) | 0.002 |  | – |
Received WBC transfusion | 31 (23) | 24/206 (12) | 0.004 |  | – |
Year of IA diagnosis/treatment |  |  | < .0001 |  | – |
 1993–2004 | 99 (75) | 87 (42) |  |  |  |
 2005–2016 | 33 (25) | 121 (58) |  |  |  |
Prophylactic antifungal treatment prior to infection | 36 (27) | 76/207 (37) | 0.07 | 0.61 (0.41, 0.90) | 0.012 |
Breakthrough | 29/36 (81) | 69/75 (92) | 0.11 | Â | Â |
Primary therapy strategy | Â | Â | < .0001 | Â | < .0001 |
 Diagnostic-driven therapy with voriconazole | 2 (2) | 42 (20) |  | Referent |  |
 Empiric antifungal therapy without voriconazole | 123 (93) | 97 (47) |  | 18.0 (4.4, 73.2) | (< .0001) |
 Empiric antifungal therapy with voriconazole | 7 (5) | 69 (33) |  | 2.2 (0.5, 10.6) | (0.33) |